Skip to main content
SciBX: Science-Business eXchange
As published Thursday, December 18, 2014

  • Cover Story: Neutralizing the negatives of RNAi

    By Kai-Jye Lou, Senior Writer

    Despite years of attempts with liposomes, nanoparticles and conjugation strategies, delivery of siRNA to organs beyond the liver remains the biggest hurdle to using the technology for a host of diseases. A University of California, San Diego group has changed the rules with a prodrug strategy that delivers siRNA into cells as an uncharged oligonucleotide, bypassing the limitations of siRNA's negative charge.1 But the real breakthrough will be to show that the prodrugs work in a range of cells and tissues that standard siRNAs cannot easily reach.

    Solstice Biologics LLC obtained an exclusive worldwide license to the technology last year and set up shop to translate the strategy into therapeutics. The company was cofounded by Steven Dowdy, the UCSD investigator behind the invention, and Curt Bradshaw, who is CSO.

    Full Article


  • This Week in Therapeutics

    Using chemically modified carbohydrates as cancer vaccine antigens; preventing doxorubicin-induced cardiotoxicity with ophiopogonin D; inhibiting VEGF receptor to treat tuberculosis; and more...

  • more therapeutics news
  • This Week in Techniques

    High throughput, miniaturized chemical synthesis for lead compound discovery; antimiR-peptide conjugates that cross cell membranes; a four-gene panel for diagnosing eosinophilic esophagitis; and more...

  • more techniques news
Subscribe Now
Free Trial